# Forge Biologics Patient Advocacy Memo

* *Forge Biologics adds Duke University School of Medicine as a Clinical Trial Site*

**COLUMBUS, OHIO June 26, 2024** – Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced that it has added the Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine, as a clinical trial site for its REKLAIM trial with Dr. Joanne Kurtzberg as acting Principal Investigator (PI).

REKLAIM is a Phase 1b, nonblinded, non-randomized dose escalation clinical trial currently enrolling children with asymptomatic infantile and symptomatic late infantile Krabbe disease to investigate the safety and efficacy of a single intravenous infusion of FBX-101 administered more than 21 days after HSCT, the current standard of care, when the patient is at different stages of immune competence. Data from an extensive natural history study of untreated and transplanted subjects will be used to compare as the control group. The FBX-101-REKLAIM trial was modified in the fourth quarter of 2023 to allow a broader patient recruitment of infantile and late infantile Krabbe patients. The updated REKLAIM study merges the recruitment populations of the RESKUE (NCT04693598) and the REKLAIM clinical trial (NCT05739643). More information on the REKLAIM trial can be found online at <https://clinicaltrials.gov/study/NCT05739643>.

Forge’s active clinical trial sites include:

**University of Michigan Medical Center**

PI: Mark Vander Lugt, M.D.

**Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine**

PI: Joanne Kurtzberg, M.D.

**Families and Clinician Inquiries**

Maria Escolar, M.D.

Chief Medical Officer

[advocacy@forgebiologics.com](mailto:advocacy@forgebiologics.com)